High sensitivity, increased specificity, and improved precisionfor accurate prediction of recurrence and better stratification of patients with improved PFS over genomic-only methods1,2
Tissue-Free Sampling
Enhanced Performance
9-day average turnaround time for MRD in the clinical setting4
MRD, molecular residual disease; PFS, progression-free survival.
Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
QUANTIFY CANCER
Guardant Infinity enables liquid-only MRD and response monitoring that is accessible and scalable across clinical trials.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
Blood-based testing eliminates tissue procurement barriers and increases patient evaluability in clinical studies3